Drug Type Bispecific T-cell Engager (BiTE), TCR therapy |
Synonyms Anti-Mutant P53 TCR-T, HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy, p53 R175H |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), p53 R175H inhibitors(Cellular Tumor Antigen p53 R175H inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Affini-T Therapeutics, Inc.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | Affini-T Therapeutics, Inc.Startup | 15 Mar 2024 |